An Important Check-Up On ImmunityBio Inc (NASDAQ: IBRX)

ImmunityBio Inc (IBRX) concluded trading on Wednesday at a closing price of $5.71, with 4.15 million shares of worth about $23.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 273.20% during that period and on April 3, 2024 the price saw a gain of about 8.35%. Currently the company’s common shares owned by public are about 670.87M shares, out of which, 131.91M shares are available for trading.

Stock saw a price change of 11.52% in past 5 days and over the past one month there was a price change of 12.62%. Year-to-date (YTD), IBRX shares are showing a performance of 13.75% which increased to 213.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.25 but also hit the highest price of $6.93 during that period. The average intraday trading volume for ImmunityBio Inc shares is 4.05 million. The stock is currently trading 7.11% above its 20-day simple moving average (SMA20), while that difference is up 22.94% for SMA50 and it goes to 78.15% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


ImmunityBio Inc (NASDAQ: IBRX) currently have 670.87M outstanding shares and institutions hold larger chunk of about 8.49% of that.

The stock has a current market capitalization of $3.85B and its 3Y-monthly beta is at 1.17. It has posted earnings per share of -$1.13 in the same period. It has Quick Ratio of 5.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 12.77% while standing at 10.22% over the month.

Analysts are in expectations that ImmunityBio Inc (IBRX) stock would likely to be making an EPS of -$0.16 in the current quarter, while forecast for next quarter EPS is -$0.17 and it is -$0.45 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.16 which is -$0.16 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.27 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 40.87% while it is estimated to increase by 33.82% in next year. EPS is likely to shrink at an annualized rate of -1.70% for next 5-years, compared to annual growth of 1.17% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on May 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $10 and $4 to it. Coverage by Jefferies stated ImmunityBio Inc (IBRX) stock as a Buy in their note to investors on August 03, 2022, suggesting a price target of $8 for the stock.

Most Popular

Related Posts